ERBB2 and neoplasm: We found that MED1 overexpression greatly promotes MMTV-HER2 mammary tumor formation by as early as 6–8 weeks, although MED1 overexpression itself only modestly affects mammary gland ductal growth during the early pubertal stage and does not induce hyperplasia or tumor formation.